Lichenoid Dermatitis From Interferon alpha-2a in a Patient With Metastatic Renal Cell Carcinoma and Seronegative HCV.

Abstract

<p>Cutaneous reactions to interferon, including a lichenoid drug reaction, are most commonly reported in patients undergoing treatment for hepatitis C virus (HCV) infection. There have been case reports of interferon-induced lichen planus in seronegative HCV patients with lymphoproliferative disorders and melanoma. We report the case of a 71-year-old man undergoing treatment with interferon for metastatic renal cell carcinoma (RCC) who developed an eruption 2 months after starting interferon. Clinical and histological findings from biopsies supported a diagnosis of interferon-induced lichen planus. To our knowledge, this is the first known case of a lichenoid drug eruption from interferon in a seronegative HCV patient with metastatic RCC.</p> <p><em>J Drugs Dermatol. 2017;16(7):714-716.</em></p>.

• Authors: Amelia E Bush, Sharon R Hymes, Sirunya Silapunt
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 16 Issue 7 Pg. 714-716 (Jul 01 2017) ISSN: 1545-9616 [Print] United States
• PMID: 28697228 (Publication Type: Case Reports, Journal Article)

Chemical References

• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins

Topics

• Aged
• Carcinoma, Renal Cell (drug therapy)
• Drug Eruptions (diagnosis)
• Hepacivirus
• Humans
• Interferon alpha-2
• Interferon-alpha (adverse effects)
• Kidney Neoplasms (drug therapy)
• Lichenoid Eruptions (chemically induced, diagnosis)
• Male
• Recombinant Proteins (adverse effects)